leadf
logo-loader
viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals halted ahead of ArtemiC phase-II clinical trial interim results

The European-based biopharma company recently received an initial purchase order from LYPHE for 900 units of its affordable Mercury Pharma medicine line of products.

MGC Pharmaceuticals Ltd -  Title
The size of the first commercial order is the largest single order for MGC Pharmaceuticals into the UK to date

MGC Pharmaceuticals Ltd (ASX:MXC) (OTCMKTS:MGCLF) has interim results pending on an ArtemiC phase-II clinical trial and has been granted a trading halt by the ASX.

The trading halt will remain in place until the start of regular trading on Friday, August 21, or when an announcement is released to the market, whichever occurs earliest.

MGC Pharma has a market cap of approximately $42.4 million and shares last traded at 2.6 cents.

Largest order to date into the UK

A distribution agreement was recently signed with UK medical cannabis provider LYPHE Group Limited to distribute its EU GMP cannabinoid medicines into the growing UK market for medical cannabis products.

The European-based biopharma company specialising in the production and development of phytocannabinoid-derived medicines, has already received an initial purchase order from LYPHE for 900 units of its affordable Mercury Pharma medicine line of products.

This is a direct shipment sale and not consignment stock, indicating the immediate patient demand from the LYPHE network.

The size of this first commercial order from LYPHE is the largest single order for MGC Pharmaceuticals into the UK to date.

It is strategically important for MGC Pharma as it demonstrates a valuable commercial channel into the UK.

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.024 AUD

ASX:MXC
Market: ASX
Market Cap: $39.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: THC Global Group granted GMP Licence for Southport cannabis...

THC Global Group Limited (ASX:THC) chief executive officer Ken Charteris updates Proactive on being granted a licence to manufacture therapeutic goods for the company’s Southport Facility, known as a GMP Licence, by the Australian Therapeutic Goods Administration (TGA). This milestone...

on 28/1/20

2 min read